Your browser is no longer supported. Please, upgrade your browser.
Settings
PSDV pSivida Corp. daily Stock Chart
PSDV [NASD]
pSivida Corp.
Index- P/E- EPS (ttm)-0.52 Insider Own0.10% Shs Outstand39.02M Perf Week-2.44%
Market Cap46.82M Forward P/E- EPS next Y- Insider Trans145.31% Shs Float36.83M Perf Month-1.64%
Income-18.50M PEG- EPS next Q-0.15 Inst Own26.40% Short Float2.79% Perf Quarter-11.11%
Sales7.50M P/S6.24 EPS this Y23.20% Inst Trans-76.43% Short Ratio2.07 Perf Half Y-32.20%
Book/sh0.34 P/B3.53 EPS next Y- ROA-91.40% Target Price9.17 Perf Year-47.37%
Cash/sh0.43 P/C2.77 EPS next 5Y- ROE-134.30% 52W Range1.03 - 2.45 Perf YTD-29.82%
Dividend- P/FCF- EPS past 5Y15.20% ROI-139.70% 52W High-51.02% Beta1.34
Dividend %- Quick Ratio3.40 Sales past 5Y16.40% Gross Margin- 52W Low16.50% ATR0.06
Employees22 Current Ratio3.40 Sales Q/Q133.30% Oper. Margin- RSI (14)47.44 Volatility4.08% 4.56%
OptionableYes Debt/Eq0.00 EPS Q/Q15.50% Profit Margin- Rel Volume1.56 Prev Close1.20
ShortableYes LT Debt/Eq0.00 EarningsSep 11 AMC Payout- Avg Volume496.09K Price1.20
Recom1.70 SMA20-1.48% SMA50-0.58% SMA200-25.91% Volume772,036 Change0.00%
May-30-17Initiated Rodman & Renshaw Buy $8
Oct-15-15Initiated FBR Capital Outperform $6
Sep-29-14Reiterated Northland Capital Outperform $7 → $10
May-05-14Initiated MLV & Co Buy $6
Oct-18-13Reiterated Ladenburg Thalmann Buy $5 → $2.75
Oct-08-13Initiated Northland Capital Outperform $7
Apr-10-13Upgrade Ladenburg Thalmann Neutral → Buy $4
Nov-18-09Initiated Ladenburg Thalmann Buy $9
Oct-18-17 07:00AM  pSivida Corp. Announces First Quarter Fiscal Year 2018 Financial Results Release Date and Conference Call Information GlobeNewswire
Oct-10-17 11:44AM  ETFs with exposure to pSivida Corp. : October 10, 2017 Capital Cube
10:18AM  Biotech Stocks Ignite in the News on Tuesday ACCESSWIRE
07:00AM  pSivida and Nicox Enter Strategic Collaboration Agreement to Develop Sustained Release Drug to Lower Intraocular Pressure in Patients with Glaucoma GlobeNewswire
01:32AM  Nicox and pSivida enter strategic collaboration agreement to develop sustained release drug to lower intraocular pressure in patients with glaucoma GlobeNewswire
Oct-05-17 09:33AM  pSivida Corp. :PSDV-US: Earnings Analysis: Q4, 2017 By the Numbers : October 5, 2017 Capital Cube +5.88%
Oct-04-17 07:10AM  Earnings Review and Free Research Report: pSividas Revenue Surged 52.2%; Net Loss Narrowed ACCESSWIRE
Sep-26-17 07:00AM  pSivida Partners with Global Pharmaceuticals Company to Develop Sustained Release Formulations of Glaucoma Drugs GlobeNewswire
Sep-22-17 02:29PM  pSivida to Present at the Ladenburg Thalmann 2017 Healthcare Conference GlobeNewswire
Sep-18-17 06:36PM  ETFs with exposure to pSivida Corp. : September 18, 2017 Capital Cube +5.79%
07:40AM  Earnings Review and Free Research Report: Catalents Revenue Grew 16%; Adjusted EPS Jumped 25% ACCESSWIRE
Sep-15-17 02:08PM  pSivida Corp. :PSDV-US: Earnings Analysis: 2017 By the Numbers : September 15, 2017 Capital Cube
Sep-12-17 07:46PM  Edited Transcript of PSDV earnings conference call or presentation 11-Sep-17 8:30pm GMT Thomson Reuters StreetEvents -5.11%
Sep-11-17 04:01PM  pSivida Corp. Achieves Significant Milestones Throughout FY 2017; Reports Fourth Quarter and Fiscal 2017 Results GlobeNewswire +7.03%
11:00AM  Investor Network: pSivida Corp Shs Chess Depository Interests repr 1/40 Sh to Host Earnings Call ACCESSWIRE
07:00AM  pSivida to Present at Rodman & Renshaw Annual Global Investment Conference GlobeNewswire
06:27AM  Is pSivida Corp (PSDV) Undervalued? Simply Wall St.
Sep-05-17 07:00AM  pSivida Corp. to Report Fourth Quarter and Fiscal Year 2017 Financial Results on Monday, September 11th GlobeNewswire
Aug-01-17 07:00AM  pSivida to Present at Canaccord Genuity Growth Conference on August 10, 2017 GlobeNewswire
Jul-18-17 07:00AM  Leading Retinal Specialists to Highlight pSividas Durasert for Treatment of Posterior Segment Uveitis at Prestigious Ophthalmology Conferences GlobeNewswire
Jul-10-17 04:56PM  Alimera Sciences To Expand ILUVIEN® Indication in Europe for Posterior Uveitis GlobeNewswire -5.68%
04:01PM  pSivida Out-licenses EMEA Rights for Durasert Three-year Treatment for Posterior Segment Uveitis While Retaining U.S. Commercial Rights; Amended Global Collaboration Agreement with Alimera for ILUVIEN® Improves pSividas Revenue Generation GlobeNewswire
Jun-28-17 07:00AM  pSivida Enhances Board of Directors with Election of Veteran Healthcare Executive Kristine Peterson GlobeNewswire
Jun-22-17 07:00AM  pSivida Submits Marketing Authorization Application (MAA) for Approval of Durasert Three-year Treatment for Posterior Segment Uveitis in the European Union GlobeNewswire
06:20AM  Watertowns pSivida files for European approval of treatment to prevent blindness American City Business Journals
Jun-14-17 08:00AM  Today's Research Reports on Stocks to Watch: SodaStream International and pSivida Corp. Accesswire
Jun-13-17 07:00AM  pSividas Durasert Three-year Treatment for Posterior Segment Uveitis Successfully Achieves Primary Efficacy Endpoint in Second Phase 3 Study GlobeNewswire -15.87%
Jun-09-17 06:36AM  Edited Transcript of PSDV earnings conference call or presentation 4-May-17 8:30pm GMT Thomson Reuters StreetEvents
Jun-07-17 07:30AM  Why This $1.00 Medical Device Stock is Set Up to Rip Accesswire
May-22-17 02:02PM  ETFs with exposure to pSivida Corp. : May 22, 2017 Capital Cube
May-11-17 05:23PM  ETFs with exposure to pSivida Corp. : May 11, 2017 Capital Cube
May-10-17 10:49AM  pSivida Corp. :PSDV-US: Earnings Analysis: Q3, 2017 By the Numbers : May 10, 2017 Capital Cube
May-08-17 09:15AM  Durasert Three-year Treatment for Posterior Segment Uveitis Significantly Reduces Recurrences Through 12 Months GlobeNewswire
08:00AM  Today's Research Reports on Kratos Defense & Security Solutions and pSivida Post Earnings Accesswire
May-05-17 01:45PM  Edited Transcript of PSDV earnings conference call or presentation 4-May-17 8:30pm GMT Thomson Reuters StreetEvents +17.26%
May-04-17 07:00PM  PSivida reports 3Q loss Associated Press
04:01PM  pSivida Corp. Reports Fiscal 2017 Third Quarter Results; Key Milestones on Track GlobeNewswire
09:45AM  Investor Network: pSivida Corp. to Host Earnings Call Accesswire
Apr-19-17 04:01PM  pSivida Corp. to Report Third Quarter Fiscal Year 2017 Financial Results on Thursday, May 4th GlobeNewswire
Apr-11-17 02:23PM  ETFs with exposure to pSivida Corp. : April 11, 2017 Capital Cube
Mar-29-17 08:35PM  ETFs with exposure to pSivida Corp. : March 30, 2017 Capital Cube
08:35PM  ETFs with exposure to pSivida Corp. : March 30, 2017
Mar-20-17 08:30AM  pSivida Corp. :PSDV-US: Earnings Analysis: Q2, 2017 By the Numbers : March 20, 2017 Capital Cube
08:30AM  pSivida Corp. :PSDV-US: Earnings Analysis: Q2, 2017 By the Numbers : March 20, 2017
Mar-15-17 07:00AM  Abstract on pSivida's Treatment of Posterior Segment Uveitis Accepted for Presentation at the 2017 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting GlobeNewswire
Mar-06-17 08:32AM  PSIVIDA CORP. Files SEC form 8-K, Other Events
Feb-15-17 01:04PM  PSIVIDA CORP. Financials
Feb-10-17 07:00AM  pSivida to Present at the 2017 BIO CEO & Investor Conference GlobeNewswire
Feb-09-17 04:18PM  PSIVIDA CORP. Files SEC form 10-Q, Quarterly Report +5.68%
Feb-08-17 04:12PM  PSIVIDA CORP. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits +6.02%
Feb-07-17 09:19PM  Edited Transcript of PSDV earnings conference call or presentation 7-Feb-17 9:30pm GMT Thomson Reuters StreetEvents
05:30PM  PSivida posts 2Q loss Associated Press
04:04PM  PSIVIDA CORP. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:01PM  pSivida Corp. Reports Fiscal 2017 Second Quarter and First Half Results GlobeNewswire
07:07AM  Q2 2017 pSivida Corp Earnings Release - After Market Close
Jan-25-17 07:00AM  pSivida Corp. Announces Second Quarter Fiscal Year 2017 Financial Results Release Date and Conference Call Information GlobeNewswire
Jan-10-17 04:32PM  PSIVIDA CORP. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits +10.58%
Dec-30-16 08:32AM  PSIVIDA CORP. Files SEC form 8-K, Termination of a Material Definitive Agreement, Change in Directors or Principal Of
Dec-23-16 12:34PM  PSIVIDA CORP. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits +7.07%
Dec-20-16 08:35AM  PSIVIDA CORP. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Dec-16-16 07:58PM  pSivida Corp. (PSDV): Heres How It Stacks Up Versus Its Peers Insider Monkey +8.12%
07:58PM  pSivida Corp. (PSDV): Heres How It Stacks Up Versus Its Peers at Insider Monkey
04:07PM  PSIVIDA CORP. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of Secur
Dec-13-16 11:45AM  ETFs with exposure to pSivida Corp. : December 13, 2016 -8.24%
Dec-02-16 01:07PM  ETFs with exposure to pSivida Corp. : December 2, 2016
Nov-10-16 12:56PM  ETFs with exposure to pSivida Corp. : November 10, 2016
Nov-09-16 11:57AM  pSivida Corp. :PSDV-US: Earnings Analysis: Q1, 2017 By the Numbers : November 9, 2016
Nov-08-16 01:45PM  PSIVIDA CORP. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
Nov-07-16 10:39PM  Edited Transcript of PSDV earnings conference call or presentation 7-Nov-16 9:30pm GMT +5.61%
05:04PM  PSivida reports 1Q loss
04:15PM  Seasoned Ophthalmology Executive Deb Jorn Joins pSivida to Focus on Corporate and Commercial Development GlobeNewswire
04:07PM  PSIVIDA CORP. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:01PM  pSivida Corp. Reports Fiscal 2017 First Quarter Results and Provides Update on Corporate Objectives & Milestone Timeline GlobeNewswire
07:07AM  Q1 2017 pSivida Corp Earnings Release - After Market Close
Oct-31-16 07:00AM  pSivida Corp. Announces First Quarter Fiscal Year 2017 Financial Results Release Date and Conference Call Information GlobeNewswire
Oct-28-16 03:15PM  ETFs with exposure to pSivida Corp. : October 28, 2016
Oct-18-16 10:59AM  ETFs with exposure to pSivida Corp. : October 18, 2016
Oct-17-16 09:16AM  pSivida Corp. :PSDV-US: Earnings Analysis: 2016 By the Numbers : October 17, 2016
Oct-04-16 07:00AM  Phase 3 trial of Medidur in Posterior Segment Uveitis Meets Enrollment Target GlobeNewswire
Oct-03-16 11:18AM  ETFs with exposure to pSivida Corp. : October 3, 2016
Sep-28-16 04:03PM  PSIVIDA CORP. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
Sep-27-16 07:00AM  pSivida Corp. Strengthens Board of Directors With Leading Ophthalmologist GlobeNewswire
Sep-22-16 09:00AM  pSivida to Present at the Ladenburg Thalmann Annual Healthcare Conference GlobeNewswire
Sep-20-16 05:17PM  PSIVIDA CORP. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
04:01PM  pSivida Reports Inducement Awards to New President and Chief Executive Officer GlobeNewswire
Sep-15-16 11:25AM  Watertown's pSivida appoints new CEO to focus on commercialization at bizjournals.com
07:00AM  pSivida Implements Leadership Change -- Nancy Lurker Named as President and CEO GlobeNewswire
Sep-13-16 02:30PM  PSIVIDA CORP. Files SEC form 10-K, Annual Report
02:03AM  Edited Transcript of PSDV earnings conference call or presentation 12-Sep-16 8:30pm GMT
Sep-12-16 04:17PM  PSivida reports 4Q loss AP
04:02PM  PSIVIDA CORP. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:01PM  pSivida Corp. Provides Company Update and Reports Fourth Quarter and FY 2016 Results GlobeNewswire
07:07AM  Q4 2016 pSivida Corp Earnings Release - After Market Close
Sep-01-16 10:00AM  pSivida Corp. Announces Fourth Quarter and Fiscal Year 2016 Financial Results Release Date and Conference Call Information GlobeNewswire
Aug-29-16 10:00AM  pSivida Announces 13 New Patents Issued or Allowed GlobeNewswire
Aug-15-16 09:00AM  Topline Results from First Phase 3 Trial of pSividas Medidur Presented at ASRS Annual Meeting GlobeNewswire
Aug-09-16 10:00AM  Primary Endpoint Met in pSividas Utilization Study of New Medidur Inserter with Smaller Diameter Needle GlobeNewswire
Aug-03-16 08:00AM  pSivida Names Dario Paggiarino, M.D. as Chief Medical Officer GlobeNewswire
Aug-01-16 07:00AM  pSivida Corp and Hospital for Special Surgery Innovation Center Announce Opening of IND for Sustained-Release Implant for Severe Knee Osteoarthritis GlobeNewswire
Jul-27-16 04:25PM  pSivida Corp.: Strong price momentum but will it sustain?
pSivida Corp. develops sustained-release drug-delivery products for the treatment of chronic eye diseases in the United States and the United Kingdom. It offers ILUVIEN, an injectable, sustained-release micro-insert for use in treating vision impairment associated with diabetic macular edema; and Retisert for the treatment of posterior segment uveitis. The company is also developing Medidur, an injectable, sustained-release micro-insert, which is in Phase III clinical trials for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. Its pre-clinical development program focuses on developing products using its core platform technologies, Durasert and Tethadur, to deliver drugs and biologics to treat wet and dry age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. The company has strategic collaborations with Alimera Sciences, Inc.; Pfizer, Inc.; Bausch & Lomb Incorporated; and Enigma Therapeutics Limited. pSivida Corp. was founded in 1987 and is headquartered in Watertown, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lurker NancyPresident and CEOJun 14Buy1.7656,70099,96256,700Jun 14 04:05 PM